A new Chinese-developed GLP-1 weight loss drug could prove a new competitor to blockbuster drugs Ozempic/Wegovy and Zepbound, clinical trial results show. Ecnoglutide helped people lose between 9% to 13% of their body weight on average after 40 weeks of treatment, according to phase 3 trial findings published June 21 in The Lancet Diabetes & Endocrinology. That average weight loss rose to more than 15% by week 48 on the heaviest dose of ecnoglutide, researchers reported in updated trial results presented Saturday at the American Diabetes Association’s annual meeting in Chicago. Overall, nearly 93% of trial participants lost 5% or more of their body weight, nearly seven times the weight loss achieved by a control group given a placebo, researchers said. Those results outperformed the Chinese clinical trials of semaglutide (Ozempic) and tirzepatide (Zepbound), which helped 85% to 88% of participants lose 5% of more of their weight, researchers noted in their paper. Participants “continued to have weight loss at week 48 without reaching a plateau, indicating that even greater weight loss might be achievable with extended ecnoglutide treatment,” lead researcher Dr. Linong Ji of the Peking University People’s Hospital in Beijing said in a news release. “Considering the high potency of ecnoglutide, it might also serve as a viable option for individuals who do not achieve sufficient weight reduction with existing GLP-1 receptor agonists… read on > read on >







